#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Liposarcoma metastatic General anaesthesia Erdheim-Chester disease Metastases to central nervous system Glomerulonephritis membranous Mucous membrane pemphigoid Hypertriglyceridaemia Growth hormone deficiency Thrombocytopenia Urea cycle disorder Follicular lymphoma stage I Nodal marginal zone B-cell lymphoma Glomerulonephritis minimal lesion Gaucher's disease type III Alveolar proteinosis More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent – Trials in Disease Proteus syndrome – Life with Disease Gastrointestinal stromal tumour – Diagnostics Alternating hemiplegia of childhood – Treatment VEXAS syndrome – Trials in Disease Mantle cell lymphoma stage IV – Trials in Disease Brain stem glioma – Basic Information Ewing’s sarcoma metastatic – Trials in Disease Congenital generalised lipodystrophy – Basic Information Marfan’s syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ht-29-B Miransertib Motixafortide Peginterferon Alfa-2A Methionine Tipiracil Esflurbiprofen Nortriptyline Hydrochloride A3907 Obinutuzumab Colistimethate Sodium GRISNILIMAB SETARITOX Amoxicillin Sodium Emraclidine Metolazone Busulfan Amlodipine Siltuximab Dopamine Hydrochloride Tulisokibart More therapies…

    Learn about Your Condition

    Rabies Meningorrhagia Hip arthroplasty Post-traumatic headache Haemoptysis Vulvovaginal discomfort Shock Gaucher's disease type I Malabsorption Incontinence Contusion Turner's syndrome Heart transplant Osteoporosis postmenopausal HIV infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uncategorized

  • Switch maintenance with paclitaxel, ramucirumab and tislelizumab versus continued chemotherapy with tislelizumab in HER2‑negative, PD‑L1‑positive gastroesophageal cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Ramucirumab
    • Calcium Folinate
    • Cisplatin
    Germany Italy Spain

  • Tacrolimus for prevention of post-ERCP pancreatitis in moderate- to high-risk patients

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • Tacrolimus
    The Netherlands

  • Effect of dapagliflozin and semaglutide on heart insulin resistance in type 2 diabetes patients

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Dapagliflozin Propanediol
    • Semaglutide
    Spain

  • Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

    Not yet recruiting

    3 1 1
    Investigated Drugs:
    • ADMILPARANT
    Austria Belgium Denmark Finland France Germany +8

  • Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

    Not yet recruiting

    4 1 1
    Investigated Drugs:
    • Efgartigimod Alfa
    Austria Germany

  • Evaluation of recurrence‑free survival with cemiplimab immunotherapy in medically inoperable stage I non‑small cell lung cancer patients

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Cemiplimab
    The Netherlands
Previous Page
1 … 693 694 695 696 697 … 1,657
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!